SCM
HELP

Squadron Capital Management’s Helus Pharma Inc. Common Stock HELP Stock Holding History

Squadron Capital Management’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-525,000
Closed -$4.29M – 41
2025
Q4 		$4.29M Buy
+525,000
New +$3.38M 1.82% 17

Other funds holding HELP

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Squadron Capital Management's HELP Position: Q1 2026 in Review

Squadron Capital Management sold out of Helus Pharma Inc. Common Stock (HELP) in Q1 2026, closing a stake of 525,000 shares — an estimated $4.29M sold.

Squadron Capital Management first reported a position in HELP in Q4 2025 and held it in 1 quarter. The position peaked at $4.29M in Q4 2025. 81 funds tracked by Wall St. Rank hold HELP as of Q1 2026.

  • Squadron Capital Management reported no remaining Helus Pharma Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
  • Squadron Capital Management sold 525,000 Helus Pharma Inc. Common Stock shares in Q1 2026, an estimated $4.29M.
  • Squadron Capital Management first reported a position in Helus Pharma Inc. Common Stock in Q4 2025 and held it in 1 quarter.
  • Squadron Capital Management's Helus Pharma Inc. Common Stock position peaked at $4.29M in Q4 2025.
  • 81 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q1 2026.

Based on Squadron Capital Management's 13F filing for Q1 2026, filed 15 May 2026.